Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805818 · ClinicalTrials.gov registry record · Phase 2
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT00805818 is a Phase 2 study that has completed, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 261 participants.
The verdict
NCT00805818, a Phase 2 study, has completed, sponsored by Neuren Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Interventions
- DRUG Placebo
- DRUG NNZ-2566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805818
The ClinicalTrials.gov registry entry for NCT00805818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuren Pharmaceuticals Limited, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00805818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805818 about?
NCT00805818 is a clinical study titled "Study of NNZ-2566 in Patients With Traumatic Brain Injury". The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
What is the current status of trial NCT00805818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2010-04. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00805818?
The interventions under investigation include: Placebo (DRUG), NNZ-2566 (DRUG).
Who is sponsoring clinical trial NCT00805818?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.